Pages Menu
Categories Menu

Posted by on Jan 27, 2011 in Foundation NewsLine |

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Clinical Trials

A note from Genzyme – January 2011:

Genzyme is continuing efforts to develop recombinant human acid sphingomyelinase (rhASM) for the potential treatment of the non-neurological manifestations of acid sphingomyelinase deficiency (ASMD, also known as Niemann-Pick disease Types A and B). After completing the Phase 1 clinical trial in 2009, we engaged regulatory authorities in discussion about plans for a Phase 2 clinical trial and conducted additional preclinical research in 2010. This regulatory dialogue is ongoing. We remain committed to the development of a therapy for ASMD and will keep the community informed once our regulatory discussions are complete and we can confirm a start date for the Phase 2 clinical trial for Niemann-Pick B patients.

We are pleased to note that an abstract from the Phase 1 clinical trial was selected for a podium presentation by Dr. Margaret McGovern at the 7th annual lysosomal disease network’s WORLD conference, to be held in Las Vegas, February 16-18, 2011.

Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142

(To learn more about Niemann-Pick Disease, visit To learn more about these clinical trials, please visit the National Niemann-Pick Disease Foundation’s Enzyme Replacement Therapy page.)

(function($) { function setup_collapsible_submenus() { var $menu = $('#category_mobile_menu'), top_level_link = '#category_mobile_menu .page_item_has_children > a'; $menu.find('a').each(function() { $(this).off('click'); if ( $(this).is(top_level_link) ) { $(this).attr('href', '#'); } if ( ! $(this).siblings('.children').length ) { $(this).on('click', function(event) { }); } else { $(this).on('click', function(event) { event.preventDefault(); $(this).parent().toggleClass('visible'); }); } }); } $(window).load(function() { setTimeout(function() { setup_collapsible_submenus(); }, 700); }); })(jQuery);